Drug intelligence / Profile preview

HS-10504

Development stage: Phase 3
Lead developer: Hansoh Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

HS-10504 is a fourth-generation, small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor specifically designed to target the EGFR C797S mutation, which is associated with resistance to earlier generations of EGFR inhibitors in non-small cell lung cancer (NSCLC). Developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, HS-10504 is currently being evaluated in Phase 1 clinical trials for advanced or metastatic NSCLC. The drug acts as an antagonist of the EGFR pathway and aims to overcome acquired resistance mechanisms that limit the efficacy of existing therapies for patients with EGFR-mutant NSCLC[1][2][3][4][6][8][9].

Targets

EGFR C797S (Epidermal Growth Factor Receptor C797S)

Beyond the preview

Go deeper on HS-10504.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-10504.

Explore the full profile